⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802371 | 1.00 | — | — | |
| SCHEMBL678126 | 1.00 | — | — | |
| Cadaverine Tartrate SCHEMBL2841061 | 0.85 | — | — | |
| Ethylene SCHEMBL9699905 | 0.79 | — | — | |
| SCHEMBL1326512 | 0.78 | — | — | |
| SCHEMBL9252531 | 0.77 | — | — | |
| SCHEMBL9875875 | 0.75 | — | — | |
| SCHEMBL9257895 | 0.75 | — | — | |
| SCHEMBL8345431 | 0.74 | — | — | |
| SCHEMBL8866960 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080131511-A1 | Pharmaceutical Composition for Treatment of Tear and Salivary Fluid Drying | ASTELLAS PHARMA, INC. | 2008-06-05 | — | — | US | claimed |
| US-20070105934-A1 | Pharmaceutical composition for treatment of tear and salivary fluid drying | ASTELLAS PHARMA INC. (JP) | 2007-05-10 | — | — | US | claimed |
| EP-1712230-A1 | PHARMACEUTICAL COMPOSITION FOR XEROPHTHALMIA AND XEROSTOMIA TREATMENT | Astellas Pharma Inc. (JP) | 2006-10-18 | — | — | EP | claimed |
| EP-1758597-B1 | USE OF DRUG COMBINATIONS FOR TREATING INSULIN RESISTANCE | DIAMEDICA INC (CA) | 2012-09-12 | — | — | EP | disclosed |
| US-20100008899-A1 | METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS | DIAMEDICA, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| US-20090233995-A1 | Use of drug combinations for treating insulin resistance | DIAMEDICA INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-20080131511-A1 | Pharmaceutical Composition for Treatment of Tear and Salivary Fluid Drying | ASTELLAS PHARMA, INC. | 2008-06-05 | — | — | US | disclosed |
| US-20070105934-A1 | Pharmaceutical composition for treatment of tear and salivary fluid drying | ASTELLAS PHARMA INC. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1712230-A1 | PHARMACEUTICAL COMPOSITION FOR XEROPHTHALMIA AND XEROSTOMIA TREATMENT | Astellas Pharma Inc. (JP) | 2006-10-18 | — | — | EP | disclosed |
| EP-0590150-B1 | (-)-(S)-2,8-DIMETHYL-3-METHYLENE-1-OXA-8-AZASPIRO 4,5]DECANE L-TARTRATE | YAMANOUCHI PHARMA CO LTD (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5403931-A | Storage stability; for treating Alzheimer*s | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0590150-A1 | (-)-(S)-2,8-DIMETHYL-3-METHYLENE-1-OXA-8-AZASPIRO 4,5]DECANE L-TARTRATE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992020683-A1 | (-)-(S)-2,8-DIMETHYL-3-METHYLENE-1-OXA-8-AZASPIRO[4,5]DECANE L-TARTRATE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-11-26 | — | — | WO | disclosed |